

12^a
ACTUALIZACIÓN
en el TRATAMIENTO
LEUCEMIA
AGUDA 2023



del 5 al 7
OCT
2023

Dr. Naval Daver

MD Anderson Cancer Center, Houston, USA

Dr Naval Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease, and is principal investigator on more than 25 ongoing clinical trials in these diseases, including multiple potential national and international registration studies and label enabling trials.

These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel and rational combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing FLT3 inhibitor based combinations, monoclonal antibodies, immune checkpoints, CD47, NK and T-cellular therapy approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials. Dr Daver has published over 450 peer-reviewed pubmed indexed manuscripts and is on the editorial board of hematology journals. He also serves as Chair on numerous international leukemia meetings and educational platforms
